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Pancreaticcancerisahighlyaggressivemalignancywithapoorprognosisanddeeplyaﬀectsthelifeofpeople.Therefore,theearlier
diagnosis and better treatments are urgently needed. In recent years, the proteomic technologies are well established and growing
rapidly and have been widely applied in clinical applications, especially in pancreatic cancer research. In this paper, we attempt
to discuss the development of current proteomic technologies and the application of proteomics to the ﬁeld of pancreatic cancer
research. This will explore the potential perspective in revealing pathogenesis, making the diagnosis earlier and treatment.
1.Introduction
Pancreatic cancer is a highly aggressive malignancy with a
poor prognosis; however, the present treatments are inca-
pableofproducingadesiredeﬀect.Thepatientsgenerallydie
within six months after diagnosis, and the overall ﬁve-year
survival rate is less than 5% [1]. Its incidence is increasing in
China and other countries. Therefore, the earlier diagnosis
and better treatments are urgently needed. In recent years,
the development of quantitative proteomics technology has
stimulated considerable interest in applying the technology
for clinical applications, such as revealing pathogenesis,
making the diagnosis earlier, and treatment. In this paper,
we provide an overview of recent ﬁndings in proteomics of
pancreatic cancer.
2. The Outline of Proteomics Research
Theterm“proteome”wasﬁrstusedin1994anddescribesthe
entiresetofproteinsexpressedbyagivengenome,cell,tissue,
or organism [2]. Initially, the word proteomics referred to
the techniques used to analyze a large number of proteins
at the same time; however, at present this word covers
any approach that yields information on the abundance,
properties, interactions, activities, or structures of proteins
in a sample.
Proteomics is the main tool for proteome research. The
rapid development of proteomics was made possible by the
progress in analytical instrumentation, especially in mass
spectrometry, and it is increasingly becoming the foundation
in leading scientiﬁc workgroups and in clinical research labs.
Current proteomics research can be deﬁned as two
types [3] (i) cell-mapping proteomics which aims to deﬁne
protein-proteininteractionstobuildapictureofthecomplex
networks that constitute intracellular signaling pathways
and (ii) protein expression proteomics and which monitors
global expression of large numbers of proteins within a cell
type or tissue and quantitatively identiﬁes how patterns of
expression change in diﬀerent circumstances.
3. The Methods of ProteomicsAnalysis
A proteomics analysis usually consists of two steps, protein
separation and protein identiﬁcation. Several technologies,
such as two-dimensional polyacrylamide gel electrophoresis
(2DE) and other nongel-based separation techniques, mass
spectrometry (MS), and protein microarrays, are relatively
common. Moreover, phosphoproteomics is a novel method
which makes fully use of these technologies and is frequently
used in medical studies, such as signal transduction and the
studiesofcancer.Itisanimportantcomplementoftheclassic
methods to study multiple kinases and its products.
3.1. Gel-Based Separation Techniques. Gel-based methods
are well-deﬁned techniques in the proteomic ﬁeld and are
the most commonly used. The central method for proteomic2 International Journal of Proteomics
analysis is two-dimensional gel electrophoresis (2DE). The
technique was established in 1975 and is still an important
research tool. It is developed to separate complex protein
mixtures into orthogonal separated components by isoelec-
tric point and molecular weight [4].
Two-dimensional diﬀerence gel electrophoresis (2D-
DIGE) is a diﬀerential method for comparing two protein
samples. It combines conventional 2DE with the sensitivity
of ﬂuorescent protein labeling for analytical gels and mass
ﬁnger print analysis by mass spectrometry for preparative
gels used for protein identiﬁcation. Rong et al. [5] used
aﬃnity column enrichment and DIGE to identify proteins
diﬀerentially expressed in serum from pancreatic cancer
patients. They found that mannose-binding lectin 2 and
myosin light chain kinase 2 protein were overexpressed in
serum from pancreatic cancer patients, and these proteins
might be potential biomarkers of pancreatic cancer. 2D-
DIGE eﬀectively solves the reproducibility setback of 2-DE,
giving more accurate and reliable quantiﬁcation information
of protein abundance. An additional advantage of DIGE is
that it can detect isoform changes, such as posttranslational
modiﬁcation or alternative spicing [6].
3.2. Nongel-Based Separation Techniques. Non-gel-based
separation techniques provide additional information which
is used to detect low-abundant or hydrophobic (membrane)
proteins. Alternative approaches use gel-free techniques by
combining liquid chromatography and mass spectrometry.
The signiﬁcant advantages of these techniques over 2DE
are potential high-throughput capabilities, possibility of full
automation, direct integration with MS, higher sensitivity,
and the smaller amount of starting material needed [7].
Liquid chromatographic (LC) methods are most used
to fractionate samples, which is based on two or more
bioph ysicalcharacteristics,suchassurfacecharge,h ydropho-
bicity, or aﬃnity to particular compounds. Furthermore, 2D
chromatographic strategy termed multidimensional protein
identiﬁcation technology (MudPIT) has been extensively
applied to proteomics analyses at a peptide level. Surface-
enhanced laser desorption/ionization time-of-ﬂight mass
spectrometry (SELDI-TOF MS), normal-phase/reversed-
phase high-performance liquid chromatography (NP/RP-
HPLC), and combined fractional diagonal chromatography
(COFRADIC) are usually applied in medical research. It
should be emphasized that none of these methods enables
conclusions to be drawn regarding relative protein concen-
trations [8].
MS is an analytical technique that measures the mass-to-
charge ratio (m/z) of charged particles. It is used to deter-
mine masses of particles, elemental composition of a sample
or molecule, and the chemical structures of molecules, such
as peptides and other chemical compounds. MS plays a
central role in proteomics and is emerging as the preferred
method for the characterization of the protein components
[9]. There are many types of mass spectrometers that can
be used for proteomic studies, such as time-of-ﬂight (TOF),
quadrupole (Q), triple quadrupole or linear ion trap (LIT),
ion trap (IT), Fourier transform ion cyclotron resonance
(FTICR), and Orbitrap. Being highly sensitive and extremely
accurate, MS is used to discover early biomarkers of cancer.
The limitations of MS are low-throughput capabilities, large
protein samples and insuﬃciency of low-abundance proteins
sensibility. Moreover, the type of MS technique used can
aﬀect the interpretation of the data retrieved which might
lead to an element of subjectivity [10].
The development of nongel-based “shotgun” proteomic
techniques was the remarkable advances in proteomic
technologies in the last decade. MudPIT has provided
powerful tool to study large-scale protein expression and
characterization in complex biological systems [11, 12].
Current methods for protein quantiﬁcation mostly involve
the use of electrospray ionization (ESI), matrix-assisted
laserdesorption ionization (MALDI), SELDI, isotope-coded
aﬃnity tags (ICAT and iTRAQ), isotope-coded protein
labeling (ICPL), tandem mass tags (TMT) and 15N/14N
metabolic labeling, and so forth. These methods provide
valuable ﬂexibility to study protein changes in complex sam-
ples, and can measure the slight changes (<2-fold) between
samples [13]. The promising prospects of the quantitative
proteomicsaregainingmoreandmoreinterestinbiomedical
research. Particularly, precise quantitative measurements
are key to understand the relationships between normal
cellular biology and the aberrant biology observed in cancer.
Recently, iTRAQ has been optimized to quantiﬁcate proteins
in pancreatic cancer serum [14]. Zhao et al. [15] used stable
isotope labeling technology for quantitative study to mea-
sure protein synthesis in pancreatic cancer cells. However,
most quantiﬁcation approaches are far from perfect, such
as increased time and complexity of sample preparation,
requirement for higher sample concentration, and high cost
of the reagents.
3.3. Protein Microarrays. Protein microarray provides a
multiplex approach to identify protein-protein interactions,
the substrates of protein kinases, transcription factor pro-
tein activation, or the targets of biologically active small
molecules. Three types of protein microarrays currently
used to study the biochemical activities of proteins are
analytical microarrays, functional microarrays, and reverse
phase microarrays [16]. The most common protein microar-
ray is the antibody microarray. Related microarray tech-
nologies also include DNA microarrays, cellular microar-
rays, antibody microarrays, tissue microarrays, and chem-
ical compound microarrays [17]. Protein microarray is
increasingly applied for high-throughput protein analyses in
many research areas. Schr¨ oder et al. [18] recently used an
optimized extensive protein microarray for the serum and
urine samples of pancreatic cancer patients. However, the
detection of low-abundance proteins yet remains a problem,
and the sensitivity and reproducibility need to be improved.
3.4. Phosphoproteome. Phosphoproteomics is a branch of
proteomics, and it is useful in characterizing proteins con-
taining a phosphate group as a posttranslational modiﬁca-
tion. Compared to expression analysis, phosphoproteomics
provides two additional layers of information. (i) It provides
c l u e so nw h i c hp r o t e i no rp a t h w a ym i g h tb ea c t i v a t e d .
(ii) It indicates which proteins might be potential drugInternational Journal of Proteomics 3
targets. It can analyze the entire phosphorylation-based
signaling networks [19]. For example, by phosphoproteome
and transcriptome analyses, Nagashima et al. [20] recently
found that histidine-rich-glycoprotein- (HRG-) stimulated
molecular activation was signiﬁcantly related to cancer
pathways in pancreatic cancer.
Enrichment strategies and MS analysis are usually
applied in phosphoproteomics. However, there are still a few
limitations for these techniques. Firstly, isolation methods
need to be improved, for instance, antiphosphotyrosine
antibodies are incapable of distinguishing between isolating
tyrosine-phosphorylated proteins and proteins associated
with tyrosine-phosphorylated proteins. Secondly, some rel-
evant proteins may be missed because the extraction con-
ditions are not encompassing. Therefore, proteins in very
low abundance, or phosphorylated as a target for rapid
degradation, may be missed [21].
4. Proteomics StudiesinPancreaticCancer
4.1. In Search of Pancreatic Cancer Pathogenesis. The trans-
forming growth factor-beta (TGF-beta)-Smad signaling
pathway has a pivotal role in inhibiting the growth of tumor
cells.Ijichi et al. reported that the mutation or deletion of the
Smad4 gene is foundin 50% of pancreatic cancers[22].Jazag
et al. [23] established Smad4 knockdown (S4KD) pancreatic
cancer cell lines and screened for the targeted molecules
downstream of TGF-beta using cDNA microarray and found
that the signaling pathways were diﬀerent according to the
Smad4 status. By 2DE and LC-MS/MS, Mikuriya et al. [24]
observed that 4 of 11 spots overexpressed in pancreatic
cancer were the enzymes involved in glycolytic pathway,
while increased glycolysis has been regarded as the eﬀect
of intratumoral hypoxia and is possibly associated with
tumor invasion, metastasis, or resistance to therapies. Dai
et al. [25] studied the proteome of pancreatic cancer stem
cells using a capillary scale shotgun technique. By coupling
oﬀ-line capillary isoelectric focusing (cIEF) with nano-
reversed phase liquid chromatography (RPLC) followed by
spectral counting peptide quantiﬁcation, they identiﬁed 169
diﬀerentially expressed proteins, of which 24% are upregu-
lated. Ingenuity pathway analysis of these diﬀerential expres-
sion signatures further suggested signiﬁcant involvement of
signaling pathways related to apoptosis, cell proliferation,
inﬂammation, and metastasis. It was also noteworthy that
the expression of mucins-1 was upregulated, which could
enhance invasiveness of pancreatic cancer cells by inducing
epithelial to mesenchymal transition [26].
Diabetes mellitus is associated with pancreatic cancer in
more than 80% of the cases. Basso et al. [27]a n a l y z e da
series of pancreatic cancer cell lines in conditioned media,
pancreatic cancer patients’ peripheral and portal sera, and
compared them with controls’ and chronic pancreatitis
patients’ sera by MALDI-TOF. A tumor-derived peptide of
14 amino acids sharing a 100% homology with an S-100
calcium-binding protein was identiﬁed, which was therefore
suggested to be a pancreatic cancer-associated diabetogenic
factor. This study might provide new insights into the
mechanism of the pancreatic cancer-associated diabetes. It
could be referred that many proteins might play certain
important roles in pancreatic cancer’s genesis.
4.2. In Discovery of the Pancreatic Cancer Biomarkers.
T h ea p p l i c a t i o n so fp r o t e o m i c st e c h n i q u e sc a ns c r e e na n d
identify the immunogenic membrane antigens in high-risk
population for early diagnosis of pancreatic cancer. The
serum glycosylation marker CA19-9 is the most commonly
used marker in pancreatic cancer. The results of Navaglia
et al. [28] suggested that the combination of CA 19-9
and SELDI-TOF/MS features could improve the diagnostic
accuracy of CA 19-9. SELDI-TOF/MS allows identiﬁcation
of new peptides, which in addition to CA 19-9 enables
the correct classiﬁcation of the vast majority of patients
with pancreatic cancer. By immunohistochemistry, oligonu-
cleotide microarray, and serial analysis of gene, Koopmann
et al. [29] recently also found that serum macrophage
inhibitory cytokine-1 (MIC-1) is a new marker of pancreatic
cancer. The combination of MIC-1 and CA19-9 signiﬁcantly
improved the diagnostic accuracy, with a sensitivity of 70%
and a speciﬁcity of 85%. Matsubara et al. [30] identiﬁed a
signiﬁcant decrease of the plasma CXC chemokine ligand
7(CXCL7) level in pancreatic cancer. The combination of
CA19-9 with CXCL7 improved the discriminatory power
over the former alone for pancreatic cancer diagnosis. These
ﬁndings may provide a new diagnostic option for pancreatic
cancer and facilitate early detection of the disease. Other
proteins were also identiﬁed as new potential discriminating
markers of pancreatic cancer, such as phosphoglycerate
kinase (PGK) 1, histone H4 cyclin I, Rab GDP dissociation
inhibitor b (GDI2), and serotransferrin platelet factor 4
(PF4) [31–33].
Primarily by 2-DE analyses, pancreatic juice was exten-
sively studied and led to discovery of several pancreatic
enzymes in the late 1970s and 1980s [34]. At present, more
and more techniques are applied in pancreatic juice research.
Tian et al. [35] carried out DIGE and MS/MS to compare the
pancreatic juice proﬁling from pancreatic ductal adenocarci-
noma (PDAC) patients and cancer-free controls. The present
proteome analysis revealed that matrix metalloproteinase-9
(MMP-9), oncogene DJ1 (DJ-1), and alpha-1B-glycoprotein
precursor (A1BG) proteins were elevated in pancreatic
juice from PDAC patients, which suggested their further
utility in PDAC diagnosis. Kojima reported that speciﬁc
urine biomarkers distinguished malignancy from chronic
inﬂammation using the method of MALDI-MS and MS/MS
[36].
4.3. In the Treatment of Pancreatic Cancer. The level of
activation/repression of multiple regulated proteins involved
in the PDAC processes correlates with the growth inhibition
and the apoptotic response of the cells subjected to single
or combined drug treatment [37]. Mori-Iwamoto et al.
[38] performed proteomic analysis (2-DE, LC-MS/MS) and
found that seven proteins, including heat stress protein
(HSP) 27, peroxiredoxin 2, endoplasmic reticulum protein
(Erp) 29 precursor, 6-phosphogluconolactonase, triosephos-
phate isomerase, alpha enolase, and nucleophosmine, could
play a role in estimating the sensitivity of pancreatic cancer4 International Journal of Proteomics
to gemcitabine. The sensitivity to gemcitabine was restored
by knocked down HSP27 in resistant pancreatic cancer cells,
while increased HSP27 expression was related to higher
resistibility. Furthermore, KNK437, an HSP inhibitor, down-
regulated HSP27 of pancreatic cancer cells and enhanced
the cytotoxic eﬀect of gemcitabine [39]. Hereby, HSP27 may
be involved in the resistance to gemcitabine and could be a
possible predictor of the response to gemcitabine-based reg-
imen. Kuramitsu et al. [40] identiﬁed the proteins mediating
the poor response of pancreatic cancer to gemcitabine by
2DE and MS.
Taniuchi et al. [41] introduced immunohistochemistry,
MS analysis, semiquantitative RT-PCR, and Northern blot
analysisintoidentifyingnovelmoleculartargetsforthetreat-
ment of PDAC. Their results suggested that collaboration of
kinesin RAB6KIFL and discs large homologue 5 (DLG5) was
likely to be involved in pancreatic carcinogenesis. Synuclein-
gamma overexpression was observed in pancreatic cancer
with perineural invasion and lymph node metastasis. It was
found to be the only independent predictor of diminished
overall survival and the strongest negative indicator of
disease-free survival [42]. These molecules might be promis-
ingtargetsfordevelopment ofnewtherapeuticstrategiesand
allow a rational and individualized therapy for pancreatic
cancer [43].
The study of Shields et al. [44] on retinoblastoma-
binding protein (RBBP) 9, a tumor-associated serine hydro-
lase, is worth noting. By using LC/LC MS/MS, activity-based
proteomic proﬁling (ABPP) coupled to MudPIT, immuno-
precipitation, and immunoblot, these authors found that
RBBP9 displayed elevated activity in pancreatic carcinomas,
which overcame TGF-beta-mediated antiproliferative signal-
ing by reducing Smad2/3 phosphorylation. The expression
of E-cadherin was required in this process, and the decrease
of the levels of E-cadherin will lead to reducing the integrity
of tumor cell-cell junctions. These data demonstrated that
functional proteomics has a potential beneﬁt in the identiﬁ-
cation of new therapeutic targets.
5. Conclusion
Proteomics is a rapidly developing science and oﬀers assis-
tance in the diagnosis and treatment of pancreatic cancer.
However, certain potential diﬃculties have also been recog-
nized. The sensitivity, speciﬁcity, and reproducibility of the
available molecular markers are still below the expectation
[45]. With the improvement of proteomics technology,
this branch of science would surely become the potential
and essential tool for the early diagnosis and treatment of
pancreatic cancer.
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